Capsaicin
- Generic Name
- Capsaicin
- Brand Names
- Capzasin Quick Relief, Capzasin-HP, Castiva Warming, Dendracin Neurodendraxcin, Lidopro, Medi-derm, Medi-derm With Lidocaine, Medrox, Qutenza, Rematex, Xoten-C, Zostrix
- Drug Type
- Small Molecule
- Chemical Formula
- C18H27NO3
- CAS Number
- 404-86-4
- Unique Ingredient Identifier
- S07O44R1ZM
- Background
Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.
- Indication
The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.
- Associated Conditions
- Back Pain Lower Back, Back pain, Bursitis, Contusions, Inflammatory Reaction caused by Rheumatism, Muscle Cramps, Musculoskeletal Pain, Neuropathic Pain, Osteoarthritis (OA), Pain caused by Rheumatism, Periarthritis, Soft Tissue Injury, Tendinitis, Acute nonspecific tenosynovitis, Articular inflammation
Capsaicin to Control Pain Following Third Molar Extraction
- Conditions
- Facial Pain
- First Posted Date
- 2001-01-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Target Recruit Count
- 162
- Registration Number
- NCT00008476
- Locations
- 🇺🇸
National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States
Positron Emission Tomography to Measure Pain and Pain Control
- Conditions
- HealthyPainHyperalgesiaPeripheral Nervous System Disease
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Target Recruit Count
- 273
- Registration Number
- NCT00001307
- Locations
- 🇺🇸
National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States
Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis
- Conditions
- Interstitial CystitisVulvar Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2025-05-04
- Target Recruit Count
- 139
- Registration Number
- NCT00004316
- Locations
- 🇺🇸
University of Pittspurgh, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.